South Korea Approves Hanmi's EPPE, the First Homegrown GLP-1 Obesity Drug

What Happened

South Korea's Ministry of Food and Drug Safety (MFDS) has approved EPPE, an obesity treatment developed in-house by Hanmi Pharmaceutical — the first GLP-1 weight-management drug developed domestically in Korea and the country's 45th homegrown new drug. The approval, announced October 7, 2026, covers the EPPE Auto-Injector in five strengths (2, 4, 6, 8 and 10 mg), with efpeglenatide as the active ingredient.

EPPE is a long-acting GLP-1 receptor agonist built on Hanmi's proprietary Lapscovery platform. Like Wegovy and Mounjaro, it mimics the GLP-1 hormone that the gut releases after meals, acting on receptors in the hypothalamus and gastrointestinal tract to suppress appetite and slow gastric emptying. It is indicated for chronic weight management in adults with obesity or overweight who do not have diabetes, as an adjunct to a reduced-calorie diet and exercise.

The decision rests on interim Phase 3 results from 448 Korean participants, who recorded an average body-weight reduction of 9.75%, with some participants losing up to 30% of body weight. Among female participants with a body mass index below 30, average weight loss reached 12.20%. Domestic reporting also notes the drug was developed with Korean BMI characteristics in mind and is expected to carry relatively fewer gastrointestinal side effects such as vomiting.

Who Is Affected

• Korean patients with obesity — a locally manufactured GLP-1 alternative arrives in a market dominated by imported drugs, with supply planned by year-end.
• Novo Nordisk and Eli Lilly — both filed for South Korean approval of their oral obesity medicines this year; EPPE now precedes them as the local first mover.
• Asian gray-market sellers — an approved domestic alternative narrows the space in which unregulated "research use only" copies compete.
• Investors — Hanmi Science shares surged roughly 14% in after-market trading on the approval day.

Timeline

• 2015 — Hanmi licenses efpeglenatide to Sanofi for global development.
• 2020 — Hanmi takes the rights back and continues development on its own.
• Late 2025 — Phase 3 completed; Hanmi files for product approval with the MFDS.
• October 7, 2026 — MFDS approves EPPE Auto-Injector as Korea's 45th new drug.
• By end of 2026 — planned domestic launch from the Pyeongtaek bio plant; a separate Phase 3 trial for diabetes use is under way.

What This Means for Researchers

• Efpeglenatide is now a fully registered long-acting GLP-1 agonist with a public regulatory dossier — a new molecule entering the legal supply chain alongside semaglutide and tirzepatide.
• The Phase 3 dataset is drawn from a homogenous East Asian population, addressing a gap in a field where pivotal obesity trials enroll predominantly Western participants.
• The molecule's history — licensed to a global pharma, reclaimed, and pushed over the finish line domestically — is a case study in how regional firms are moving from importer to developer.
• For anyone sourcing GLP-1-related compounds, the arrival of a legitimately approved Asian competitor matters: legal access expands, and the justification for unregulated gray-market supply shrinks further.

How to Verify Your Peptides

• How third-party lab testing works
• HPLC versus LC-MS: what each method reveals
• Identity, purity and fill-weight reports explained

Safe Alternatives

• Documented compounds in the research-grade peptide landscape
• Vetted suppliers in the vendor directory

Sources

Regulatory announcements; industry reports.